Myriad BRCA Patents Nixed: What Happens Next?

Medscape

Last week a Supreme Court ruling brought a multiyear legal battle to a close, with its unanimous decision that "products of nature" cannot be patented. At the heart of the ruling were the BRCA1 and BRCA2 genes, which were patented by Myriad Genetics in the late 1990s.
But as the ink dries and the dust settles, the bigger question looms: what does this really mean for oncology practice and cancer patients, in both the long and short term?......